Vivoo today announces FlowPad, the world’s first hygienic menstrual pad with a built-in microfluidic diagnostic system, turning menstrual blood into clear, actionable hormone and vaginal-health insights without requiring any change in routine. Already a CES Innovation Award winner, FlowPad signals a major leap forward in how women can access and understand their health data.
FlowPad looks and feels like a familiar menstrual pad, yet inside it carries an elegant, sealed diagnostic architecture capable of analyzing menstrual biomarkers with lab-grade precision. By tapping into one of the richest, yet historically overlooked, biological resources, menstrual blood, FlowPad transforms a routine monthly experience into a powerful source of insight, autonomy, and early detection.
“Women deserve diagnostics that fit their real lives, intuitive, hygienic, and deeply insightful,” said Miray Tayfun, CEO and Co-Founder of Vivoo. “FlowPad shows how an everyday biological process can become a powerful source of knowledge. This is the future of hormone health accessible, effortless, and human-centered.”
FlowPad ,along with the commercial version of the Vivoo Smart Toilet, also debuting at CES 2026, will be demonstrated throughout the show at the Vivoo booth [Venetian Expo, Halls A-D — 54118].
A Scientific Breakthrough Hidden in Plain Sight
FlowPad is the first menstrual pad ever to embed a microfluidic diagnostic layer, technology that passively captures and channels menstrual blood into controlled biomarker zones. This enables detection of clinically relevant indicators beginning with Follicle-Stimulating Hormone (FSH), a crucial hormone for fertility, ovarian health, and perimenopause transitions. At its core is a two-layer microfluidic system engineered for accurate, repeatable measurement:
- Capillary capture layer: draws in a precise volume of menstrual fluid while filtering out particulates for clean analysis.
- Biomarker reaction layer: hosts stabilized reagents that interact with hormones such as FSH and LH, producing colorimetric signatures detectable only through advanced image processing analysis.
- App-based interpretation: After wear, users simply scan FlowPad with the Vivoo App, which interprets microchannel patterns, hue shifts, and reaction intensities to deliver personalized, meaningful insights.
Everything happens fully sealed within the pad, maintaining complete hygiene and eliminating fluid handling. No swabs, no vials, no clinical appointments, just real data derived from a routine product.
A New Era: Menstrual Blood as a Diagnostic Goldmine
Hormone testing has traditionally depended on invasive blood draws, high costs, and precisely timed clinic visits. FlowPad disrupts that model entirely by transforming a naturally occurring biological event into a non-invasive, effortlessly accessible diagnostic opportunity. Menstrual blood contains an extraordinary spectrum of biomarkers that mirror what’s happening across the endocrine system, from fertility and ovarian reserve to cycle regularity, perimenopause transitions, stress responses, inflammation, and even long-term metabolic health. With FlowPad, this information is no longer discarded; it becomes meaningful, monthly intelligence.
Once scanned, the Vivoo App converts FlowPad’s microfluidic signatures into clear explanations and personalized insights. This makes the system relevant for women tracking fertility, those experiencing irregular cycles, individuals in their late twenties through forties as hormonal patterns begin to shift, and anyone navigating the uncertainty of perimenopause or monitoring how stress and inflammation affect their body. It also offers clinicians, telehealth providers, and researchers a new window into population-scale hormone data without the friction of traditional testing.
The Vivoo App goes far beyond simply displaying results. Its AI engine interprets menstrual biomarkers, maps cycle-specific patterns and builds longitudinal hormone trends over time. These insights are enriched through integration with hydration, nutrition, and lifestyle data already supported within the Vivoo ecosystem, and they can be shared securely with clinicians when needed. As Vivoo expands its connected health platform, FlowPad will also synchronize with upcoming Smart Bathroom technologies, creating a more complete, continuous picture of women’s health.
FlowPad hints at a future where clinical-grade hormone insights are woven seamlessly into daily life. With additional biomarkers on the way, from LH and estrogen metabolites to cortisol, inflammation, iron, infection markers, and vaginal pH, the diagnostic power of the menstrual cycle is only beginning to be unlocked.
Pricing & Availability
FlowPad will debut publicly at CES 2026 at Vivoo Booth #54118 (Venetian Expo, Halls A–D).
Estimated price: USD $4–5 per pad, with subscription and pack configurations to be announced closer to launch. Early access will prioritize researchers, medical partners, and existing Vivoo users.
About Vivoo
Vivoo is a leading wellness technology company transforming how people measure, understand, and manage their health from home. Through next-gen diagnostics and a human-centered design approach, Vivoo creates intuitive tools that turn everyday biological signals into powerful guidance for better living.